학술논문

Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A- LONG and B- LONG clinical studies.
Document Type
Article
Source
Haemophilia. Nov2016, Vol. 22 Issue 6, p866-872. 7p. 4 Charts, 1 Graph.
Subject
*HEMOPHILIA treatment
*BLOOD coagulation factor VIII
*BLOOD coagulation factor IX
*QUALITY of life
*PREVENTIVE medicine
Language
ISSN
1351-8216
Abstract
Introduction In haemophilia, prophylactic infusion of replacement factor can result in improvements in health-related quality of life (HRQoL) when compared with episodic treatment. The Haemophilia-specific Quality of Life (Haem-A-QoL) questionnaire assessed HRQoL in adults with severe haemophilia A or B who received prophylactic or episodic treatment with recombinant factor VIII or IX Fc fusion protein ( rFVIIIFc or rFIXFc) in the A- LONG or B- LONG clinical studies. Aims Understand changes in HRQoL during the A- LONG and B- LONG trials. Methods Group-level and individual-level changes over time for the Haem-A-QoL key domains of 'Physical Health' and 'Sports & Leisure,' and 'Total Score' were evaluated in adults through baseline and 6-month HRQoL assessments. Previously determined responder definitions ( RDs) were used for evaluating meaningful subject-level HRQoL improvements. Results The analysis included 67 A- LONG and 51 B- LONG subjects who completed the Haem-A-QoL (baseline and 6 months). While HRQoL improvements were observed among all treatment groups, greater improvements in HRQoL were observed among subjects who received episodic treatment pre-study (and prophylaxis on-study) compared to those who received hyphenate prophylaxis. Applying the RDs for interpreting 6-month changes, 47.4%/33.3% ('Physical Health'), 35.9%/50.0% ('Sports & Leisure') and 23.9%/33.3% ('Total Score') of A- LONG subjects who received individualized or weekly prophylaxis were classified as HRQoL responders. In B- LONG, 69.2%/57.9% ('Physical Health'), 44.4%/56.7% ('Sports & Leisure') and 41.7%/44.1% ('Total Score') of subjects who received individualized or weekly prophylaxis were classified as HRQoL responders. Conclusion Changes in Haem-A-QoL key domains and 'Total Score' suggest that prophylaxis with long-acting rFVIIIFc or rFIXFc resulted in meaningful HRQoL improvements. [ABSTRACT FROM AUTHOR]